Your browser doesn't support javascript.
loading
Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Cobo-Calvo, Alvaro; Ruiz, Anne; Rollot, Fabien; Arrambide, Georgina; Deschamps, Romain; Maillart, Elisabeth; Papeix, Caroline; Audoin, Bertrand; Lépine, Anne Fabienne; Maurey, Hélène; Zephir, Helene; Biotti, Damien; Ciron, Jonathan; Durand-Dubief, Francoise; Collongues, Nicolas; Ayrignac, Xavier; Labauge, Pierre; Meyer, Pierre; Thouvenot, Eric; Bourre, Bertrand; Montcuquet, Alexis; Cohen, Mikael; Horello, Philippe; Tintoré, Mar; De Seze, Jerome; Vukusic, Sandra; Deiva, Kumaran; Marignier, Romain.
Afiliación
  • Cobo-Calvo A; Department of Neurology, Multiple Sclerosis and Neuroinflammation, Pierre Wertheimer Neurological Hospital, Lyon Civil Hospices, Lyon, France.
  • Ruiz A; Department of Neurology-Neuroimmunology, Multiple Sclerosis Center Catalonia, Vall d'Hebron Institute of Research, Vall d'Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain.
  • Rollot F; Lyon Neuroscience Research Center, U1028 INSERM, UMR5292 CNRS, FLUID Team, Lyon, France.
  • Arrambide G; Lyon Neuroscience Research Center, U1028 INSERM, UMR5292 CNRS, FLUID Team, Lyon, France.
  • Deschamps R; University of Lyon, Claude Bernard University Lyon 1, Lyon Civil Hospices, EDMUS Foundation, OFSEP, Lyon Neuroscience Research Center, Lyon, France.
  • Maillart E; Department of Neurology-Neuroimmunology, Multiple Sclerosis Center Catalonia, Vall d'Hebron Institute of Research, Vall d'Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain.
  • Papeix C; Department of Neurology, Adolphe de Rothschild Hospital Foundation, Paris, France.
  • Audoin B; Department of Neurology and Reference Center for Rare Inflammatory Diseases of the Brain and Bone, Pitié-Salpêtrière Hospital, Public Hospital Network of Paris, Paris, France.
  • Lépine AF; Department of Neurology and Reference Center for Rare Inflammatory Diseases of the Brain and Bone, Pitié-Salpêtrière Hospital, Public Hospital Network of Paris, Paris, France.
  • Maurey H; Aix-Marseille University, Public Assistance Hospitals of Marseille, Timone Hospital, Clinical Neuroscience Center, Neurology Department, Marseille, France.
  • Zephir H; Pediatric Neurology Department, Timone Hospital, Public Assistance Hospitals of Marseille, Marseille, France.
  • Biotti D; National Referral Center for Neuroinflammatory Diseases and Pediatric Neurology Department, Public Hospital Network of Paris, Bicêtre Hospital, Le Kremlin-Bicêtre, France.
  • Ciron J; Department of Neuropediatrics, University of Paris-Sud, Le Kremlin-Bicêtre, France.
  • Durand-Dubief F; University Lille, INSERM, CHU Lille, U1172-Laboratory of Neuroinflammation and Multiple Sclerosis, Lille Neuroscience & Cognition, Lille, France.
  • Collongues N; Department of Neurology, SEP Resource and Competence Center, Lille, France.
  • Ayrignac X; Department of Neurology, CRC-SEP, Toulouse University Hospital, Toulouse, France.
  • Labauge P; Department of Neurology, CRC-SEP, Toulouse University Hospital, Toulouse, France.
  • Meyer P; Department of Neurology, Multiple Sclerosis and Neuroinflammation, Pierre Wertheimer Neurological Hospital, Lyon Civil Hospices, Lyon, France.
  • Thouvenot E; Department of Neurology and Clinical Investigation Center, INSERM 1434, Strasbourg University Hospital, Strasbourg, France.
  • Bourre B; Department of Neurology, Montpellier University Hospital, Montpellier, France.
  • Montcuquet A; Department of Neurology, Montpellier University Hospital, Montpellier, France.
  • Cohen M; Department of Pediatric Neurology, CHU Montpellier, PhyMedExp, University of Montpellier, INSERM, CNRS, Montpellier, France.
  • Horello P; Department of Neurology, Carémeau Hospital, Nimes University Hospital, Nimes, France.
  • Tintoré M; Department of Neurology, Rouen University Hospital, Rouen, France.
  • De Seze J; Department of Neurology, Dupuytren Hospital, Limoges, France.
  • Vukusic S; Department of Neurology, CRCSEP, Cote d'Azur Clinical Research Unit, Pasteur University Hospital Center 2, Nice, France.
  • Deiva K; Division of Immunovirology, INSERM, U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, University of Paris-Sud 11, CEA, DSV/iMETI, IDMIT, Faculty of Medicine, Le Kremlin-Bicêtre, France.
  • Marignier R; Department of Neurology-Neuroimmunology, Multiple Sclerosis Center Catalonia, Vall d'Hebron Institute of Research, Vall d'Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain.
Ann Neurol ; 89(1): 30-41, 2021 01.
Article en En | MEDLINE | ID: mdl-32959427
ABSTRACT

OBJECTIVE:

The main objective was to compare clinical features, disease course, and myelin oligodendrocyte glycoprotein (MOG) antibody (Ab) dynamics between children and adults with MOG-Ab-associated disease (MOGAD).

METHODS:

This retrospective multicentric, national study included 98 children and 268 adults with MOGAD between January 2014 and September 2019. Cox regression model for recurrent time-to-event data and Kaplan-Meier curves for time to antibody negativity were performed for the objectives.

RESULTS:

Isolated optic neuritis was the most frequent clinical presentation in both children (40.8%) and adults (55.9%, p = 0.013), and acute disseminated encephalomyelitis syndrome was more frequent in children (36.7% vs 5.6%, p < 0.001). Compared to adults, children displayed better recovery (Expanded Disability Status Scale ≥ 3.0 at last follow-up reached only by 10 of 97 [10.3%] vs 66/247 [26.7%], p < 0.001). In the multivariate analysis, adults were at higher risk of relapse than children (hazard ratio = 1.41, 95% confidence interval [CI] = 1.12-1.78, p = 0.003). At 2 years, 64.2% (95% CI = 40.9-86.5) of nonrelapsing children became MOG-Ab negative compared to 14.1% (95% CI = 4.7-38.3) of relapsing children (log-rank p < 0.001), with no differences observed in adults (log-rank p = 0.280).

INTERPRETATION:

MOGAD patients differ in the clinical presentation at onset, showing an age-related shift in the clinical features across age groups. Compared to children, adults have a higher risk of relapse and worse functional recovery. Finally, children with monophasic disease become MOG-Ab negative earlier than relapsing children, but this is not true in adults. Considering these differences, management and treatment guidelines should be considered independently in children and adults. ANN NEUROL 2021;8930-41.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Autoanticuerpos / Neuritis Óptica / Acuaporina 4 / Glicoproteína Mielina-Oligodendrócito Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male Idioma: En Revista: Ann Neurol Año: 2021 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Autoanticuerpos / Neuritis Óptica / Acuaporina 4 / Glicoproteína Mielina-Oligodendrócito Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male Idioma: En Revista: Ann Neurol Año: 2021 Tipo del documento: Article País de afiliación: Francia